Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

By Jerusalem Guy   Fasolo Angelica   Dieras Veronique   Cardoso Fatima   Bergh Jonas   Vittori Luc   Zhang Yufen   Massacesi Cristian   Sahmoud Tarek   Gianni Luca  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 447-455

Springer Publishing Company

Access to resources Recommend Favorite

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

By Valabrega Giorgio  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 29-40

Springer Publishing Company

Access to resources Recommend Favorite

Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2

By McKeage K.   Perry C.M.  

American Journal of Cancer, Vol. 1, Iss. 3, 2002-03 ,pp. : 217-221

Adis International

Access to resources Recommend Favorite

A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients

By Iwata Hiroji   Narabayashi Masaru   Ito Yoshinori   Saji Shigehira   Fujiwara Yasuhiro   Usami Shigeyuki   Katsura Koichi   Sasaki Yasutsuna  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 621-628

Springer Publishing Company

Access to resources Recommend Favorite

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

By Zhu Yuanxi  

Tumor Biology, Vol. 33, Iss. 5, 2012-10 ,pp. : 1349-1362

Springer Publishing Company

Access to resources Recommend Favorite